Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | ADH7 | P40394 | 1/20 | 0.33 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | DUT | P33316 | 1/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22664469 | 0.98 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2ADH1B | |
| SCHEMBL20500262 | 0.98 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2ADH1B | |
| SCHEMBL5073223 | 0.98 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2ADH1B | |
| SCHEMBL4333525 | 0.98 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2ADH1B | |
| SCHEMBL20500283 | 0.98 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2ADH1B | |
| SCHEMBL4821411 | 0.98 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2ADH1B | |
| SCHEMBL4824010 | 0.98 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2ADH1B | |
| SCHEMBL20500252 | 0.98 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2ADH1B | |
| SCHEMBL641418 | 0.95 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2ADH1B | |
| SCHEMBL16705774 | 0.90 | HDAC1 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415770-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | Emory University, Office of Technology Transfer (US) | 2025-09-16 | — | — | US | disclosed |
| EP-4516774-A2 | MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) AND USES | Emory University (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-3595652-B1 | MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) | UNIV EMORY (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240368066-A1 | MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) AND USES | EMORY UNIVERSITY | 2024-11-07 | — | — | US | disclosed |
| US-12065402-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | EMORY UNIVERSITY (US) | 2024-08-20 | — | — | US | disclosed |
| US-20230295070-A1 | Modulators of Liver Receptor Homologue 1 (LRH-1) and Uses | EMORY UNIVERSITY | 2023-09-21 | — | — | US | disclosed |
| US-20230295070-A1 | Modulators of Liver Receptor Homologue 1 (LRH-1) and Uses | EMORY UNIVERSITY | 2023-09-21 | — | — | US | disclosed |
| US-11691939-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | EMORY UNIVERSITY (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691939-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | EMORY UNIVERSITY (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| US-7176227-B2 | For example, N-(4-{[bis(1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-N',N'-dipropylbutane-1,4-diamine; efficacious against diseases such as infection with HIV virus, rheumatism, and cancer metastasis | KUREHA CORPORATION (JP) | 2007-02-13 | — | — | US | disclosed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-20060019959-A1 | Novel quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. TSUKUBA RESEARCH INSTITUTE (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20050165063-A1 | Amine compounds and use thereof | KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED. (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1557418-A1 | NOVEL QUINOXALINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-27 | — | — | EP | disclosed |
| EP-1550657-A1 | AMINE COMPOUNDS AND USE THEREOF | Kureha Chemical Industry Co., Ltd. (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-0575494-A4 | — | — | 1994-04-20 | — | — | EP | disclosed |
| EP-0575494-A1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-12-29 | — | — | EP | disclosed |
| WO-1992016104-A1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368066-A1 | MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) AND USES | NR1H2, NR1H3, NR1H4 | SMYD2 1285/4885CYP3A4 2300/4885HTT 3051/4885 |
| US-12415770-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | NR1H2, NR1H3, NR1H4 | SMYD2 1285/4885CYP3A4 2300/4885HTT 3051/4885 |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | XDH, MYD88, IKZF3 | SMYD2 3569/4885CYP3A4 123/4885HTT 4251/4885 |
| US-20050165063-A1 | Amine compounds and use thereof | NR0B2, NR5A2, NR1H4 | SMYD2 1785/4885CYP3A4 426/4885HTT 3354/4885 |
| US-20230295070-A1 | Modulators of Liver Receptor Homologue 1 (LRH-1) and Uses | NR1H2, NR1H3, NR1H4 | SMYD2 1285/4885CYP3A4 2300/4885HTT 3051/4885 |
| US-11691939-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | NR1H2, NR1H3, NR1H4 | SMYD2 1285/4885CYP3A4 2300/4885HTT 3051/4885 |
| US-12065402-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | NR1H2, NR1H3, NR1H4 | SMYD2 1285/4885CYP3A4 2300/4885HTT 3051/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | SMYD2 1567/4885CYP3A4 409/4885HTT 3429/4885 |
| US-20060019959-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB11 | SMYD2 2787/4885CYP3A4 144/4885HTT 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.